1. Alamanos, Y., Voulgari, P. V., and Drosos, A. A. (2006): Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin.Arthritis Rheum. 3 (36): 182-188.
2. McInnes, I. B. and Schett, G. (2011): The pathogenesis of rheumatoid arthritis. N.Engl.J.Med. 23 (365): 2205-2219.
3. Josef S. Smolen, Daniel Aletaha, Anne Barton, Gerd R. Burmester, Paul Emery, Gary S. Firestein, Arthur Kavanaugh et al.Rheumatoid arthritis. Nat Rev Dis Primers 4, 18002 (2018). https://doi.org/10.1038/nrdp.2018.2
4. Yap H-Y, Tee S, Wong M, Chow S-K, Peh S-C, Teow S-Y. Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development. Cells. 2018;7(10):161. doi:10.3390/cells7100161
5. Prada Hernández D M, Hernández Torres C, Gómez Morejón J A, Gil Armenteros R, Reyes Pineda Y, Solís Carta U, Molinero Rodríguez C. Evaluación de la Calidad de vida relacionada con la salud en pacientes con artritis reumatoide en el Centro de Reumatología. Rev. Cubana de Reumatología. Volum.17, núm.1 (2015):48-60. ISSN: 1817-5996.
6. MC Domínguez, A Cabrales, N Lorenzo, G Padrón and LJ Gonzalez. Biodistribution and pharmacokinetic profiles of an Altered Peptide Ligand derived from Heat-shock proteins 60 in Lewis rats. Cell Stress and Chaperones. 2020; 25(1): 133–140.
7. Dinorah Prada, Jorge Gómez, Norailys Lorenzo, Oreste Corrales, Ana López, Evelio González, Ania Cabrales2, Yusimy Reyes, Yuliet Bermudez, Yisel Avila, Lina Pérez, Claudio Molinero, Osmel Martinez, Leonardo Oramas, Yaysel Miñoso, Yassel Ramos, Hilda Garay, Ever Pérez, Matilde López, Osvaldo Reyes, Yolanda Cruz, Alfredo Hernández, Cabal Carlos, Vladimir Besada, Luis Javier González, Gabriel Padrón and Maria del Carmen Domínguez Horta. Phase I Clinical Trial with a Novel Altered Peptide Ligand Derived from Human Heat-Shock Protein 60 for Treatment of Rheumatoid Arthritis: Safety, Pharmacokinetics and Preliminary Therapeutic Effects. J Clin Trials 2018, 8:1
8. Oreste Corrales, Laura Hernández, Dinorah Prada, Jorge Gómez, Yusimy Reyes, Ana Marta López, Luis Javier González y Maria del Carmen Domínguez Horta. CIGB-814, an altered peptide ligand derived from human heat-shock protein 60, decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis. Clinical Rheumatology (2019) 38:955–960
9. Ania Cabrales-Rico, Yassel Ramos, Vladimir Besada, María del Carmen Domínguez, Noraylis Lorenzo, Osmel García et al. Development and validation of a bioanalytical method based on LC-MS/MS analysis for the quantitation of CIGB-814 peptide in human plasma from patients with Rheumatoid Arthritis. J Pharm Biomed Anal. 2017: 5; 143:130-140.
10. Domínguez M del C, Serrano A, Hernández-Cedeño M, Martínez G, Guillén G. A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators : a therapeutic approach to infl ammation. Front Inmunol. 2023;(April):1–10.